Celcuity

Celcuity posted an Associate Director/Director of Patient Marketing role described as supporting the launch of its first product, REVTORPYK, initially focused on advanced breast cancer. It also posted an Associate Director of Congress Planning role responsible for planning, executing, and optimizing the company’s congress program in partnership with marketing, sales, market access, and medical affairs.

The company posted a Director of Biostatistics role to contribute across multiple studies, analyze and report clinical-study work, and oversee statistical programming and deliverables. A Manager of Statistical Programming posting covers programming activities from study planning through database lock, reporting, and regulatory submission.

Provider-observed headcount rose by four, or 1.5%, from 266 on September 6 to 270 on October 6. Additional postings included a formulation and process-development scientist supporting drug-product development and lifecycle management, as well as roles in program management, cybersecurity, and post-marketing pharmacovigilance. One inferred tracked departure, with role unknown, was first confirmed on September 25.